glp 1 in heart failure Effects of Glucagon-Like Peptide Receptor Agonist Initiation Patients With With Reduced Ejection Fraction and Implantable Cardiac Devices GLP-1 receptor agonists as promising

Now relief is tinged with dread

Although rigorous propensity score matching was applied to reduce confounding, residual confounding from unmeasured variables (e.g., lifestyle factors, socioeconomic status, over-the-counter medication use) cannot be excluded

Compared to the other trials investigating GLP-1RAs, the ELIXA trial included T2D patients with recent acute coronary syndrome (ACS), suggesting that perhaps their CV risk was too severe to demonstrate a simple decline in CV events via short-term pharmacological intervention

Weight loss accelerates for most users

Operational Impacts Care Management Programs: Plans must scale care management programs to handle up to 30% more members receiving GLP-1 prescriptions, requiring investment in digital tools and personnel